NCT01272050 is a Phase 3 clinical trial of radiation therapy in Prostate Cancer, sponsored by Swiss Cancer Institute.

Who is sponsoring NCT01272050?

NCT01272050 is sponsored by Swiss Cancer Institute.

What drugs are being tested in NCT01272050?

Interventions in NCT01272050: radiation therapy.

What condition does NCT01272050 study?

NCT01272050 studies Prostate Cancer.

Is NCT01272050 still recruiting?

NCT01272050 is currently completed. Last updated 28 August 2024.

Last reviewed 2024-08-28 · How we verify

NCT01272050

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery

Completed Phase 3 Last updated 28 August 2024

What this trial tests

Phase 3 trial testing radiation therapy in Prostate Cancer in 350 participants. Completed in 31 May 2024.

Timeline

6 January 2011

Primary endpoint
3 July 2020

31 May 2024

Quick facts

Lead sponsor	Swiss Cancer Institute
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	none
Primary purpose	treatment
Enrollment	350
Start date	6 January 2011
Primary completion	3 July 2020
Estimated completion	31 May 2024
Sites	28 locations across Belgium, Switzerland, Germany

Drugs / interventions tested

radiation therapy — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Swiss Cancer Institute

Who can join

Adults 18 to 75, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which radiation therapy regimen is more effective in treating patients with relapsed prostate cancer. PURPOSE: This randomized phase III trial is studying the side effects of radiation therapy and comparing two radiation therapy regimens in treating patients with relapsed prostate cancer after surgery.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.
Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, et al · · 2021 · cited 87× · PMID 34140144 · DOI 10.1016/j.eururo.2021.05.033
Delineation of the Prostate Bed: The "Invisible Target" Is Still an Issue?
Latorzeff I, Sargos P, Loos G, Supiot S, et al · · 2017 · cited 15× · PMID 28620579 · DOI 10.3389/fonc.2017.00108
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.
Dal Pra A, Ghadjar P, Ryu HM, Proudfoot JA, et al · · 2025 · cited 8× · PMID 39986927 · DOI 10.1016/j.annonc.2025.01.017
Radiation Therapy after Radical Prostatectomy: Implications for Clinicians.
Herrera FG, Berthold DR. · · 2016 · cited 8× · PMID 27242957 · DOI 10.3389/fonc.2016.00117
Hypofractionated Postoperative Radiotherapy for Prostate Cancer: Is the Field Ready Yet?
Mahase S, Nagar H. · · 2020 · cited 7× · PMID 34337473 · DOI 10.1016/j.euros.2020.10.001
Postoperative radiotherapy after radical prostatectomy: indications and open questions.
Ghadjar P, Zwahlen D, Aebersold DM, Zimmermann F. · · 2012 · cited 6× · PMID 22530131 · DOI 10.1155/2012/963417
Radiation therapy with phenotypic medicine: towards N-of-1 personalization.
Chong LM, Wang P, Lee VV, Vijayakumar S, et al · · 2024 · cited 5× · PMID 38514762 · DOI 10.1038/s41416-024-02653-3
Radiation therapy after radical surgery in prostate cancer.
Paz-Manrique R, Morton G, Vera FQ, Paz-Manrique S, et al · · 2023 · cited 5× · PMID 37396107 · DOI 10.3332/ecancer.2023.1565

Verify or expand the search:

Other trials of radiation therapy

Trials testing the same drug.

NCT03541486 — A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients · Phase 2 · withdrawn
NCT06310369 — Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer · Phase 2 · not yet recruiting
NCT04894188 — Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer · NA · recruiting
NCT05112341 — Adjuvant Whole Breast Irradiation in Five Fractions Versus Fifteen Fractions in Early Breast Cancer · unknown
NCT04594772 — Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma · Phase 2 · active not recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Swiss Cancer Institute trials

Trials by the same sponsor.

NCT07158489 — Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC · Phase 2 · not yet recruiting
NCT06835049 — Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue · Phase 2 · recruiting
NCT06452394 — NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline · Phase 2 · recruiting
NCT06114108 — Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients · NA · recruiting
NCT04629781 — Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01272050 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swiss Cancer Institute
Last refreshed: 28 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01272050.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing